Back to search results

Ziftomenib Maintenance Post Allo-HCT

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Myeloid Leukemia · Acute Myeloid Leukemia in Remission · NPM1 Mutation · KMT2A Rearrangement

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Zachariah DeFilipp, MD) · zdefilipp@mgh.harvard.edu · (617) 726-5765

  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus, Ohio, United States

    Contact: Study coordinator (Hannah Choe, MD) · Hannah.Choe@osumc.edu · 614-293-7526
    Contact: Principal Investigator (Hannah Choe, MD)
Study leads

  • Zachariah DeFilipp, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)